company background image
ISPH

Ibn Sina Pharma Company (S.A.E.)CASE:ISPH Stock Report

Market Cap

ج.م3.1b

7D

0.9%

1Y

-45.5%

Updated

21 Oct, 2021

Data

Company Financials +
ISPH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health3/6
Dividends0/6

ISPH Overview

Ibn Sina Pharma (S.A.E) operates as a pharmaceutical distributor in Egypt.

Price History & Performance

Summary of all time highs, changes and price drops for Ibn Sina Pharma Company (S.A.E.)
Historical stock prices
Current Share Priceج.م3.23
52 Week Highج.م2.99
52 Week Lowج.م6.49
Beta0.25
1 Month Change-3.58%
3 Month Change-13.17%
1 Year Change-45.53%
3 Year Change-55.50%
5 Year Changen/a
Change since IPO-36.19%

Recent News & Updates

Shareholder Returns

ISPHEG HealthcareEG Market
7D0.9%1.3%-0.8%
1Y-45.5%-14.9%11.1%

Return vs Industry: ISPH underperformed the EG Healthcare industry which returned -16.1% over the past year.

Return vs Market: ISPH underperformed the EG Market which returned 9.2% over the past year.

Price Volatility

Is ISPH's price volatile compared to industry and market?
ISPH volatility
ISPH Beta0.25
Industry Beta0.39
Market Beta1

Stable Share Price: ISPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ISPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMohamed Mohsen Mahgoubhttps://www.ibnsina-pharma.com

Ibn Sina Pharma (S.A.E) operates as a pharmaceutical distributor in Egypt. The company offers a portfolio of pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, and hospitals and healthcare institutions. It also provides warehousing and logistic services for its suppliers; marketing solutions; and importation and packaging services.

Ibn Sina Pharma Company (S.A.E.) Fundamentals Summary

How do Ibn Sina Pharma Company (S.A.E.)'s earnings and revenue compare to its market cap?
ISPH fundamental statistics
Market Capج.م3.10b
Earnings (TTM)ج.م197.23m
Revenue (TTM)ج.م19.93b

15.7x

P/E Ratio

0.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISPH income statement (TTM)
Revenueج.م19.93b
Cost of Revenueج.م18.40b
Gross Profitج.م1.53b
Expensesج.م1.33b
Earningsج.م197.23m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.21
Gross Margin7.66%
Net Profit Margin0.99%
Debt/Equity Ratio449.2%

How did ISPH perform over the long term?

See historical performance and comparison

Valuation

Is Ibn Sina Pharma Company (S.A.E.) undervalued compared to its fair value and its price relative to the market?

15.72x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ISPH (EGP3.23) is trading above our estimate of fair value (EGP2.14)

Significantly Below Fair Value: ISPH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ISPH is good value based on its PE Ratio (15.7x) compared to the African Healthcare industry average (32.3x).

PE vs Market: ISPH is poor value based on its PE Ratio (15.7x) compared to the EG market (11.6x).


Price to Earnings Growth Ratio

PEG Ratio: ISPH is good value based on its PEG Ratio (0.7x)


Price to Book Ratio

PB vs Industry: ISPH is good value based on its PB Ratio (2.2x) compared to the XF Healthcare industry average (2.8x).


Future Growth

How is Ibn Sina Pharma Company (S.A.E.) forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

24.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISPH's forecast earnings growth (24.2% per year) is above the savings rate (9.1%).

Earnings vs Market: ISPH's earnings (24.2% per year) are forecast to grow faster than the EG market (14.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ISPH's revenue (15.2% per year) is forecast to grow faster than the EG market (9.9% per year).

High Growth Revenue: ISPH's revenue (15.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ISPH's Return on Equity is forecast to be high in 3 years time (25.4%)


Past Performance

How has Ibn Sina Pharma Company (S.A.E.) performed over the past 5 years?

9.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISPH has high quality earnings.

Growing Profit Margin: ISPH's current net profit margins (1%) are lower than last year (1.4%).


Past Earnings Growth Analysis

Earnings Trend: ISPH's earnings have grown by 9.8% per year over the past 5 years.

Accelerating Growth: ISPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ISPH had negative earnings growth (-23.5%) over the past year, making it difficult to compare to the Healthcare industry average (4.5%).


Return on Equity

High ROE: ISPH's Return on Equity (16.9%) is considered low.


Financial Health

How is Ibn Sina Pharma Company (S.A.E.)'s financial position?


Financial Position Analysis

Short Term Liabilities: ISPH's short term assets (EGP8.3B) exceed its short term liabilities (EGP7.9B).

Long Term Liabilities: ISPH's short term assets (EGP8.3B) exceed its long term liabilities (EGP511.1M).


Debt to Equity History and Analysis

Debt Level: ISPH's debt to equity ratio (449.2%) is considered high.

Reducing Debt: ISPH's debt to equity ratio has reduced from 658.9% to 449.2% over the past 5 years.

Debt Coverage: ISPH's debt is not well covered by operating cash flow (6.9%).

Interest Coverage: ISPH's interest payments on its debt are not well covered by EBIT (2x coverage).


Balance Sheet


Dividend

What is Ibn Sina Pharma Company (S.A.E.) current dividend yield, its reliability and sustainability?

4.27%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISPH's dividend in 3 years as they are not forecast to pay a notable one for the EG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Mohamed Mohsen Mahgoub

0.50

Tenure

Mr. Mohamed Mohsen Mohamed Mahgoub serves as Vice Chairman and Chief Executive Officer at Ibn Sina Pharma (S.A.E) since April 2021. He served as Executive Chairman until April 2021 and has been Director at...


Leadership Team

Experienced Management: ISPH's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: ISPH's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ibn Sina Pharma Company (S.A.E.)'s employee growth, exchange listings and data sources


Key Information

  • Name: Ibn Sina Pharma Company (S.A.E.)
  • Ticker: ISPH
  • Exchange: CASE
  • Founded: 2001
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: ج.م3.101b
  • Shares outstanding: 960.00m
  • Website: https://www.ibnsina-pharma.com

Number of Employees


Location

  • Ibn Sina Pharma Company (S.A.E.)
  • Industrial Zone 1
  • El Obour City
  • 12015
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 14:31
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.